Kenvue (NYSE:KVUE) Coverage Initiated at Sanford C. Bernstein

Sanford C. Bernstein initiated coverage on shares of Kenvue (NYSE:KVUE - Free Report) in a research report released on Thursday, MarketBeat reports. The firm issued an underperform rating and a $18.00 target price on the stock.

Several other brokerages have also commented on KVUE. William Blair started coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a market perform rating on the stock. The Goldman Sachs Group started coverage on shares of Kenvue in a research report on Friday, March 1st. They set a neutral rating and a $20.00 target price on the stock. UBS Group boosted their target price on shares of Kenvue from $20.00 to $23.00 and gave the stock a neutral rating in a research report on Tuesday, December 19th. JPMorgan Chase & Co. decreased their target price on shares of Kenvue from $25.00 to $24.00 and set an overweight rating on the stock in a research report on Friday, February 9th. Finally, Royal Bank of Canada decreased their target price on shares of Kenvue from $25.00 to $24.00 and set an outperform rating on the stock in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Kenvue currently has a consensus rating of Hold and a consensus price target of $24.85.

Kenvue Price Performance

NYSE:KVUE traded down $0.78 during midday trading on Thursday, reaching $19.46. The stock had a trading volume of 25,407,879 shares, compared to its average volume of 16,978,805. The firm has a fifty day simple moving average of $19.97 and a two-hundred day simple moving average of $20.21. Kenvue has a 12-month low of $17.82 and a 12-month high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. Kenvue's revenue for the quarter was down 2.7% on a year-over-year basis. On average, sell-side analysts predict that Kenvue will post 1.17 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 4.11%. The ex-dividend date was Tuesday, February 13th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KVUE. Citigroup Inc. acquired a new position in Kenvue in the 2nd quarter valued at about $57,000. Osaic Holdings Inc. acquired a new position in shares of Kenvue during the 2nd quarter valued at about $144,000. Northern Trust Corp acquired a new position in shares of Kenvue during the 2nd quarter valued at about $1,244,000. PNC Financial Services Group Inc. acquired a new position in shares of Kenvue during the 2nd quarter valued at about $73,000. Finally, BlackRock Inc. acquired a new position in shares of Kenvue during the 2nd quarter valued at about $164,895,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.